-
AG-126: ERK Signaling in Neuroinflammation
2026-09-30
Explore how AG-126 and Tyrphostin AG-126 can help separate ERK1/2-dependent signaling from cell-type and circuit mechanisms in neuroinflammation research. This article translates inflammatory model evidence and a new striatal autism study into a cautious, causally oriented assay strategy.
-
WP1066: Cell-Permeable JAK2/STAT3 Inhibitor
2026-09-30
WP1066 is a cell-permeable JAK2/STAT3 inhibitor that suppresses phosphorylation-dependent signaling in cancer research models. Product information supports applications in renal carcinoma, acute myeloid leukemia, cancer cell proliferation assays, and pathway-focused pharmacology, while recent biomaterial research shows that activating—not inhibiting—JAK2/STAT3 can support macrophage-mediated bone repair.
-
Lambda Protein Phosphatase in BMAL1 Assays
2026-09-29
Lambda Protein Phosphatase provides a controlled way to test whether BMAL1 phosphorylation contributes to phase separation and circadian transcription. This guide presents a causal assay framework that goes beyond descriptive condensate imaging and strengthens phosphorylation site validation.
-
Carrier-Platin and the Intracellular ROS Storm
2026-09-29
Liu et al. describe carrier-platin, a polymer-confined platinum nanotherapeutic that produces a rapid intracellular ROS burst and kills cancer cells independently of DNA damage, apoptosis, or ferroptosis. The study provides a framework for evaluating ROS-generating chemotherapy against resistant tumors while highlighting the need to distinguish oxidative injury from specific regulated cell-death programs.
-
Gepotidacin Phase I PK, Safety, and Tolerability
2026-09-28
Three phase I studies characterized the pharmacokinetics, safety, and tolerability of gepotidacin (GSK2140944) after single or repeated oral dosing in healthy adults and older participants. The findings describe dose-proportional exposure, attainment of steady state, and tolerability across the tested regimens, providing a clinical pharmacology foundation for subsequent investigation.
-
Dual SORT LNPs for Multi-Organ Base Editing
2026-09-27
This study pairs organ-selective lipid nanoparticles to deliver base editors to the liver and lung in a preclinical model of alpha-1 antitrypsin deficiency. The approach achieved measurable PiZ correction in both tissues and improved disease-related readouts, while leaving human translation and long-term safety to be established.
-
Bleomycin Sulfate: Reading Fibrosis Models
2026-09-26
Bleomycin Sulfate can model DNA injury, but interpreting fibrosis requires separating initial damage from the cellular programs that build scar tissue. This article connects a recent TUG1–miR-30–SNAI2 study to practical choices in dermal fibrosis assays—and clarifies where pulmonary and cancer models differ.
-
Gepotidacin: Linking Target Activity to Exposure
2026-09-26
Explore how Gepotidacin’s distinct topoisomerase mechanism and human pharmacokinetic findings can inform more interpretable antibacterial assays. This perspective connects biochemical target engagement with exposure-aware research design while clarifying the limits of translating laboratory results.
-
Taltirelin Acetate: Assay Design for Reliable Results
2026-09-25
Learn how to use Taltirelin acetate (SKU C8755) thoughtfully in cell-based neuroprotection and Parkinson’s disease research. This scenario-driven guide covers concentration selection, assay controls, interpretation, handling, and practical product-selection criteria without treating one endpoint or model as universally predictive.
-
Multiplex PBMC Assay for Immunomodulator Screening
2026-09-25
Brox and Hackstein describe a human PBMC flow-cytometry assay that measures T-cell proliferation and activation alongside B-cell costimulatory responses. Its multiparametric readouts, Z-factor-based validation, and 295-compound pilot screen offer a practical framework for distinguishing immunomodulatory profiles while keeping primary-cell context.
-
Hoechst 33342 for TNT Transport Imaging Workflows
2026-09-24
Use Hoechst 33342 to add nuclear and cell-boundary context to live-cell studies of lipid-droplet transport through tunneling nanotubes—without mistaking a nuclear stain for a cargo or force reporter. This workflow pairs practical staining guidance with the optical-trapping findings that explain what a complementary nuclear channel can, and cannot, reveal.
-
Eudragit-Coated LNPs for Oral RNA Delivery
2026-09-24
Haque, Shrestha, and Mattheolabakis investigated whether a pH-sensitive Eudragit S 100 coating could protect lipid nanoparticles and their RNA cargo during gastrointestinal transit. The in vitro results support a formulation strategy for oral RNA delivery, while leaving in vivo absorption and efficacy to be established.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-23
Gu et al. show that CDK4/6 inhibition can restrain pancreatic tumor cell proliferation while simultaneously enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition as a complementary strategy that restores antitumor activity through coordinated regulation of GSK3β-mediated Wnt/β-catenin signaling and TGF-β/Smad pathway crosstalk.
-
Tunable Human Intestinal Organoids: Study Insights
2026-09-23
Yang and colleagues developed a human small-intestinal organoid system that maintains strong proliferation while expanding cellular diversity under a unified culture condition. The study shows that reinforcing stemness can increase, rather than suppress, differentiation potential, while BET, Wnt, Notch, and BMP pathway modulation enables reversible or directional control of intestinal cell fate.
-
Gepotidacin (GSK2140944) Research Workflows
2026-09-22
Build stronger antibacterial research workflows around Gepotidacin, from DMSO stock preparation and MIC testing to topoisomerase assays and resistance profiling. Quantitative product data and a phase 2 gonorrhea study help connect mechanistic readouts with practical assay decisions while preserving research-use boundaries.